10-K · March 23, 2026
Core Laboratories describes a technology- and IP-driven strategy focused on proprietary reservoir description and production enhancement services, international expansion and selective acquisitions. Revenue edged higher…
Earnings analysis · 10-Q
CLB earnings analysis
Filed April 30, 2026 · Our reading of the company's report
The latest report
Core Laboratories' Q1 2026 results showed a significant revenue decline to $121.8 million, down 12% sequentially and slightly down 1% year-over-year. EPS was reported at $0.06, falling short of estimates, marking a 72%…
Read full summary
Core Laboratories' Q1 2026 results showed a significant revenue decline to $121.8 million, down 12% sequentially and slightly down 1% year-over-year. EPS was reported at $0.06, falling short of estimates, marking a 72% drop from the previous quarter. Management cited geopolitical challenges and adverse weather conditions as key factors affecting performance, although they remained optimistic about long-term growth prospects in the energy market.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.06
- Operating margin
- 2%
What stood out
-
Revenue Decline
Q1 2026 revenue decreased to $121.8 million, a 12% drop sequentially and 1% down versus Q1 2025.
-
Significant EPS Drop
Reported EPS of $0.06 missed estimates by $0.04, representing a 72% decrease compared to the prior quarter.
-
Service Revenue Impact
Service revenue from the Reservoir Description segment slightly rose 1% year-over-year to $81.9 million, but fell 11% sequentially.
-
Free Cash Flow Minimized
Free cash flow was $0.5 million, a significant decline from $3.9 million year-over-year.
-
High Operating Expenses
Operating expenses increased to $102.1 million, up 3% year-over-year largely due to geopolitical impacts.
-
Debt to EBITDA Ratio Improvement
Debt to EBITDA ratio improved slightly to 1.34:1 from 1.37:1 in Q4 2025.
What to watch
-
Geopolitical Instability
Ongoing conflicts in the Middle East, especially involving Iran, have disrupted operations and raised commodity price volatilities.
-
Increased Operating Costs
Higher shipping and operational costs due to geopolitical tensions and unfavorable foreign exchange rates affected profitability.
-
Declining Demand
Lower activity levels in international markets led to decreased client demand, impacting service offerings and revenues.
Management's outlook
Management maintains a long-term optimistic outlook despite short-term geopolitical challenges.
Earlier filings 4
10-Q · October 23, 2025
Core Laboratories reported Q3 revenue of $134.521 million, essentially flat year-over-year (+$0.124 million) with margin expansion (gross ~22.0%, operating ~15.6%) and diluted EPS attributable to Core Laboratories of…
10-K · February 13, 2025
Core Laboratories reported consolidated revenue of $523.848 million for the year ended December 31, 2024, up from $509.790 million in 2023 and $489.735 million in 2022. The company emphasizes growth via proprietary…
10-Q · October 24, 2024
Core Laboratories reported quarterly revenue of $134,397,000 (Q3 2024), up versus Q3 2023 ($125,343,000) and the prior quarter, with operating income of $19,803,000 and diluted EPS of $0.25. Gross margin compressed to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.